tbuckley/cabot-search huggingface dataset:
Reply: <i>Ex vivo</i> SOCS3 gene responsiveness to alarmins in eosinophils of mepolizumab-treated patients is as yet of unknown biological significance
Authors: Glenn Van Hulst, Joseph Jorssen, Nathalie Jacobs, Monique Henket, Renaud Louis, Florence Schleich, Fabrice Bureau, Christophe J. Desmet
Journal: European Respiratory Journal (2022)

<b>It is too early to conclude on a potential biological significance of increased SOCS3 gene expression in blood eosinophils of mepolizumab-treated patients stimulated with interleukin-33 <i>ex vivo</i></b> https://bit.ly/3wuXMit
SO-39 Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100
Authors: H. Prenen, M. Fakih, G. Falchook, J. Strickler, A. Hindoyan, A. Anderson, A. Ang, T. Kurata, T. Price
Journal: Annals of Oncology (2022)

Sotorasib, a specific, irreversible KRAS G12C inhibitor, is approved in multiple countries for adults with KRAS p.G12C-mutated locally advanced or metastatic NSCLC who have received prior systemic therapy. Approval was based on the global phase 1/2 CodeBreaK 100 trial, which also investigated sotorasib in other solid tumours, including colorectal cancer (CRC). Here we describe putative mechanisms of acquired resistance to sotorasib in patients with CRC. Patients with advanced KRAS p.G12C-mutated CRC from the CodeBreaK100 phase 1/2 trial who received sotorasib monotherapy at 960 mg once daily were analysed for efficacy. The primary endpoint was objective response rate (ORR) assessed by central review. To investigate biomarkers of resistance to sotorasib, an exploratory endpoint was defined to examine acquired genomic alterations at disease progression. Plasma samples collected at baseline and progression were analysed for genomic alterations with the 74-gene Guardant 360 ® ctDNA test for CRC. Acquired genomic alterations were defined by their absence at baseline and presence at progression. In 91 patients with CRC treated with sotorasib, the ORR was 12%. At a median follow-up of 12.5 months, median progression-free survival was 4.2 months and median overall survival was 13.4 months. A total of 45 patients with CRC had a plasma sample sequenced both at baseline and at progression. At least one new acquired genomic alteration at progression was detected in 33 (73%) patients. The acquired genomic alterations were heterogeneous, with variants detected across multiple genes and pathways. The most prevalent putative pathway of resistance was found in a set of receptor tyrosine kinases (RTKs) (12 patients [27%]; including 7 patients [16%] with EGFR alterations), followed by alterations in the cell cycle pathway in 10 patients (22%) and in the DNA damage response pathway in 10 patients (22%). Secondary RAS alterations occurred in 7 patients (16%), while 27 patients (60%) had >1 alteration. Diverse mechanisms of acquired resistance occur in patients with advanced KRAS p.G12C-mutated CRC treated with sotorasib. New RTK alterations frequently emerged at progression, highlighting the potential role for combining sotorasib with upstream inhibitors of RTK, such as SHP2 or EGFR inhibitors. Serial plasma DNA analysis revealed acquired resistance patterns that support the development of KRAS G12C inhibitor combination therapies.
Benefits of specialist severe asthma management: demographic and geographic disparities
Authors: Charlene Redmond, Liam G. Heaney, Rekha Chaudhuri, David J. Jackson, Andrew Menzies-Gow, Paul Pfeffer, John Busby
Journal: European Respiratory Journal (2022)

The benefits of specialist assessment and management have yet to be evaluated within the biologic era of UK severe asthma treatment, and potential disparities have not been considered.
SO-14 Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study
Authors: M. Rimini, L. Rimassa, M. Kudo, S. Shigeo, T. Toshifumi, G. Suda, C. Yoo, J. Cheon, S. Lonardi, M. Scartozzi, E. Tamburini, G. Masi, S. Cascinu, A. Casadei-Gardini
Journal: Annals of Oncology (2022)
SO-26 Identification and quantification of the microbiome in colorectal cancer metastases
Authors: P. Stevens, V. Llorens-Rico, P. Baldin, S. Gofflot, L. Craciun, G. Fabienne, J. Sadones, M. Buys, J. Raes, M. Van Den Eynde
Journal: Annals of Oncology (2022)
SO-1 Clinical and molecular features of patients with KRAS wild-type pancreatic adenocarcinoma
Authors: I. Ben-Ammar, A. Tarabay, A. Hollebecque, M. Tanguy, V. Boige, D. Malka, C. Smolenschi, M. Ducreux, A. Boileve
Journal: Annals of Oncology (2022)
Relaxation of the criteria for entry to the UK Clozapine Central Non-Rechallenge Database: a modelling study
Authors: Ebenezer Oloyede, Eromona Whiskey, Cecilia Casetta, Olubanke Dzahini, Danielle Dunnett, Shreyans Gandhi, Fiona Gaughran, Sukhi Shergill, Philip McGuire, James H MacCabe, David Taylor
Journal: The Lancet Psychiatry (2022)
P-42 Iron surveillance and management in gastrointestinal oncology patients: A national survey of physician practice
Authors: A. Remtulla Tharani, A. Hrycyshyn, A. Abbruzzino, J. Smith, J. Kachura, M. Sholzberg, J. Mosko, S. Chadi, R. Burkes, C. Brezden-Masley
Journal: Annals of Oncology (2022)
P-165 The feasibility of tumor recurrence detection in liver post-transplantation for patients with hepatocellular carcinoma via personalized, tumor-informed ctDNA testing
Authors: M. Abdelrahim, A. Esmail, A. Saharia, A. He, H. Dhani, V. Aushev, A. Jurdi, J. Starr, P. Gauthier
Journal: Annals of Oncology (2022)
PD-7 Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma (aHCC) and previously treated gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ): Results of the COSMIC-021 study
Authors: D. Li, Y. Loriot, A. Burgoyne, J. Cleary, A. Santoro, D. Lin, S. Ponce Aix, I. Garrido-Laguna, R. Sudhagoni, J. Lougheed, S. Andrianova, S. Paulson
Journal: Annals of Oncology (2022)
P-88 Clinical role of tumour markers in advanced biliary cancers (ABC) treated with second-line active-symptom-control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial
Authors: A. Lamarca, D. Palmer, H. Wasan, P. Ross, Y. Ting Ma, A. Arora, S. Falk, R. Gillmore, J. Wadsley, K. Patel, A. Anthoney, A. Maraveyas, J. Waters, C. Hoobs, T. Macdonald, D. Ryder, J. Ramage, L. Davies, J. Bridgewater, J. Valle
Journal: Annals of Oncology (2022)

The ABC-06 clinical trial stablished ASC+mFOLFOX as the standard of care treatment after Cisplatin and Gemcitabine (CisGem) for ABC. Within the ABC-06 study, patients (pts) diagnosed with ABC (cholangiocarcinoma, gallbladder or ampullary cancer) with progression after CisGem were randomised (1:1) to ASC+mFOLFOX or ASC. Tumour markers (CA19.9, CEA and CA125), were scheduled at baseline (BSL) and at every follow-up visit. This post-hoc analysis explored if changes (stable/reducing vs increasing) of Ca19.9 at week 4 from initiation of ASC+mFOLFOX was associated with radiological progression-free survival (PFS). Secondary end-points included impact of raised BSL Ca19.9 (defined as x1.5 ULN) and chemotherapy-induced changes on overall survival (OS). CEA and CA125 were also analysed. Out 162 pts randomised, BSL Ca19.9 data was available for 135 pts. Paired BSL and week-4 Ca19.9 data was available for 37 pts in the ASC+mFOLFOX arm: Ca19.9 was stable/reducing in 17 (45.9%) and increasing in 20 pts (54.1%). Stable/reducing Ca19.9 showed a numerically longer median radiological PFS (4.3 months (m) vs 3.3m) but differences did not reach statistical significance (HR 1.08 (95% CI 0.55-2.14); p=0.81). When restricted to patients with raised BSL Ca19.9 (23 pts), impact on PFS was more marked (5.7m vs 3.2m), but remained non-significant (HR 1.68 (95% CI 0.70-4.01); p=0.23). Stable/reducing Ca19.9 at week 4 did not impact significantly on OS (p=0.56 (regardless of BSL Ca19.9 level; 37 pts); p=0.84 (if raised BSL Ca19.9; 23 pts)). Raised BSL Ca19.9 was associated both with shorter unadjusted clinical median PFS (3.2m vs 5.0m; HR 1.53 (95% CI 1.05-2.23); p=0.027) and unadjusted OS (4.4m vs 6.4m; HR 1.97 (95% CI 1.33-2.93); p When Cox Regression model (120 pts) for OS exploring the prognostic roles of raised BSL Ca19.9, CEA and CA125 was adjusted for pre-defined stratification factors (platinum sensitivity, albumin, and stage) and randomised trial arm, each raised tumour marker had an independent impact (HR 1.56 (95% CI 1.03 to 2.35); p=0.03 / HR 1.60 (95% CI 1,06 to 2.43) p=0.026 / HR 1.70 (95% CI 1.13 to 2.56); p=0.011 for Ca19.9, CEA and CA125, respectively). Unadjusted median OS was 8.9m if all tumour markers at BSL were non-raised, and 7.0m, 4.0m, 3.2m in the event of having 1, 2 or 3 raised BSL tumour markers. For ABC patients treated with second-line ASC+mFOLFOX, utility of Ca19.9 measured at week-4 after chemotherapy initiation is limited; raised BSL Ca19.9, CEA and CA125 have independent prognostic roles and future studies may need to consider these (individually or pooled) as stratification factors.
PD-9 Three-arm phase II/III randomized controlled trial in patients with unresectable/metastatic gall bladder cancer with poor performance status: Erlotinib or capecitabine v/s best supportive care
Authors: B. Kataria, A. Sharma, R. Pramanik, R. Sahoo, S. Thulkar, M. Yadav, S. Mishra, C. Prasad, S. Vishnubhatla
Journal: Annals of Oncology (2022)
P-279 A rare subset of well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG PET/CT: Is it a sign of an aggressive disease?
Authors: A. Shamseddine, L. Al Mahmasani, C. Elias, L. Chehade, S. Temraz, M. Charafeddine, M. Al Darazi, M. El Jebai, M. Haidar
Journal: Annals of Oncology (2022)
P-134 EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including multiple gastroesophageal cancer cohorts
Authors: K. Muro, J. Yang Bruce, J. Baranda, M. Campbell, C. Wu, S. Gorla, F. Braiteh
Journal: Annals of Oncology (2022)
PD-3 Phase 1 trial of vibostolimab plus pembrolizumab for PD-1/PD-L1 inhibitor-naive advanced gastric cancer: The KEYVIBE-001 trial
Authors: K. Shitara, T. Golan, K. Mileham, M. Voskoboynik, S. Rha, M. Gutierrez, R. Perets, S. Taylor, D. Chen, T. Keenan, M. Rajasagi, J. Healy, H. Shoji
Journal: Annals of Oncology (2022)
PD-2 EMERGE: A multi-centre, non-randomised, single-arm phase II study investigating domatinostat plus avelumab in patients with previously treated advanced mismatch repair-proficient oesophagogastric and colorectal adenocarcinoma
Authors: S. Slater, E. Cartwright, C. Saffery, A. Tran, G. Smith, M. Bacason, O. Zhitkov, I. Rana, E. Johnston, I. Sanna, M. Aresu, D. Kohoutova, M. Terlizzo, F. Turkes, E. Smyth, W. Mansoor, C. Fribbens, S. Rao, D. Watkins, N. Starling, I. Chau, D. Cunningham
Journal: Annals of Oncology (2022)

Mismatch repair proficient (MMRp) oesophagogastric (OG) and colorectal cancers (CRC) respond less frequently to checkpoint inhibition. Epigenetic modulation of tumours using HDAC inhibitors can increase the chance of response to immunotherapy. We previously reported dose escalation (EMERGE phase IIA) and the established recommended phase II dose (RP2D) of domatinostat (selective class I HDAC inhibitor) 200mg BID continuously plus avelumab 10mg/kg q2w. Patients with MMRp advanced OG and CRC who received at least one prior line of chemotherapy were enrolled in two cohorts. Patients were treated with a two-week domatinostat prime (orally) followed by combination domatinostat and avelumab from cycle 2 onwards. The trial was conducted using a Simon two-stage optimal design. The primary endpoint was best objective response rate (ORR) 6 months from initiation of combination treatment by RECIST 1.1. A secondary end point was disease control rate (DCR) during the same period. The total accrual target was 29 in the CRC cohort and 34 patients in the OG cohort, with interim analysis due to take place once 10 CRC patients and 9 OG patients had been evaluated for best ORR; ≥1 response and ≥2 responses were required in the respective cohorts to proceed to stage two. 21 patients were recruited between January 2020 and October 2021. In the OG cohort 9 patients were treated. 56% patients had received ≥2 prior lines of systemic anti-cancer therapy (SACT). The median duration of treatment was 1.8 months (range: 0.9-12.8). The best ORR was 22.2% [95% CI: 2.8, 60.0] (one PR and one CR). The patient with PR had a combined positive score (CPS) of 9, whilst the CPS was unavailable for the patient with CR. At time of data cut off on 25th February 2022, both patients remained on treatment at cycles 28 and 16 respectively. The median CPS for the patients whose disease did not respond to treatment was 12 (range: 0-26). In the CRC cohort, 12 patients were treated; of these, 2 did not receive avelumab and were non-evaluable. In the evaluable CRC population, 90% received ≥2 prior lines of SACT. No responses were observed. DCR was 30.0% [95% CI: 6.7, 65.2]. The median duration of treatment was 2 months (range: 1.3-9.0). The most common treatment related adverse events (TRAE) of any grade were fatigue (58%), anaemia (37%) and nausea (32%). There were no grade ≥3 TRAEs reported. For OG adenocarcinoma the ORR of 22.2% met the criteria to expand the stage two recruitment with a favourable safety profile. In CRC there was insufficient signal to progress to stage two.
P-281 Importance of tumor sampling in transcriptomics-based risk stratification
Authors: V. Popovici, T. Ivkovic, M. Hrivnakova, M. Nemecek, R. Nenutil, L. Zdražilová-Dubská, O. Slaby, B. Bencsiková, E. Budinska
Journal: Annals of Oncology (2022)
Prediction of peritoneal soiling in acute appendicitis with simple clinical and laboratory data. Prospective, multicenter, cohort study of 2,645 adult patients nationwide
Authors: N. Lluís, J. Parra, C. Villodre, P. Zapater, A. Jalali, M. Cantó, L. Mena, J.M. Ramia, F. Lluís, N. Afonso, V. Aguilella, J. Aguiló, J.C. Alados, M. Alberich, A.B. Apio, R. Balongo, E. Bra, A. Bravo-Gutiérrez, F.J. Briceño, J. Cabañas, G. Cánovas, I. Caravaca, S. Carbonell, E. Carrera-Dacosta, E. Castro E, C. Caula, E. Choolani-Bhojwani, A. Codina, S. Corral, C. Cuenca, Y. Curbelo, M.M. Delgado-Morales, L. Delgado-Plasencia, E. Doménech, A.M. Estévez, A.M. Feria, M.A. Gascón-Domínguez, R. Gianchandani, C. González, M.A. González, R.J. Hevia, J.M. Hidalgo, M. Lainez, F. López, J. López-Fernández, J.A. López-Ruíz, P. Lora-Cumplido, Z. Madrazo, J. Marchena, B. Marenco de la Cuadra, S. Martín, I. Martínez Casas, P. Martínez, A. Mena-Mateos, D. Morales-García, C. Mulas, E. Muñoz-Forner, A. Naranjo, A. Navarro-Sánchez, I. Oliver, I. Ortega, R. Ortega-Higueruelo, S. Ortega-Ruiz, J. Osorio, M.H. Padín, J.J. Pamies, M. Paredes, F. Pareja-Ciuró, C.V. Pérez-Guarinós, B. Pérez-Saborido, J. Pintor-Tortolero, K. Plua-Muñiz, M. Rey, I. Rodríguez, C. Ruiz, R. Ruíz, S. Ruiz, A. Sánchez, D. Sánchez, R. Sánchez, F. Sánchez-Cabezudo, R. Sánchez-Santos, J. Santos, M.P. Serrano-Paz, V. Soria-Aledo, L. Taccogna, L. Tallón-Aguilar, J.H. Valdivia-Risco, H. Vallverdú-Cartié, C. Varela, J. Villar-del-Moral, N. Zambudio
Journal: International Journal of Surgery (2022)
P-55 Efficacy and safety data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Real-world data from the non-interventional TACTIC study
Authors: D. Semsek, H. Kröning, T. Göhler, T. Decker, G. Kojouharoff, J. Lipke, E. Moorahrend, F. Hartmann, T. Reisländer, R. de Buhr, M. Frank, C. Hogrefe, N. Marschner, K. Potthoff, I. Schwaner
Journal: Annals of Oncology (2022)
Cold-snare endoscopic mucosal resection of large duodenal laterally spreading tumors: is cold the future gold standard?
Authors: Sophie Geyl, Marion Schaefer, Mathieu Pioche, Martin Dahan, Romain Legros, Jérémie Albouys, Jérémie Jacques
Journal: Endoscopy (2022)

Large laterally spreading tumors (LSTs) of the duodenum are considered by most experts to be very challenging benign lesions requiring endoscopic resection. Piecemeal endoscopic mucosal resection (EMR) is the gold standard but leads to a high recurrence rate and a risk of delayed bleeding.
P-149 Impact of COVID-19 pandemic and total neoadjuvant therapy (TNT) implementation in pathological complete response (pCR) rates in patients (pts) with locally advanced rectal cancer (LARC)
Authors: D. Gómez-Puerto, L. Benini, J. Hernando, A. García Álvarez, S. Vega-Cano, G. Molina Lores, J. Yaringaño, D. López, C. Salva de Torres, J. Ucha Hermida, S. Bueno, B. Navalpotro, M. Roca, F. Vallrivera Valls, M. Martí Gallostra, M. Kraft, J. Sanchez Garcia, A. Solis, F. Marinello, J. Capdevila, E. Espín Basany
Journal: Annals of Oncology (2022)
PD-10 Comprehensive circulating tumor (ct) DNA NGS for molecular profiling in advanced cholangiocarcinoma
Authors: L. Visa, T. Sauri, F. Esposito, J. Adeva Alfonso, P. Peinado, M. Ponz-Sarvise, C. Fabregat Franco, C. Carames, P. Salinas, M. Kushnir, T. Macarulla, A. Cubillo, R. Garcia-Carbonero, I. Victoria, B. Bellosillo, C. Montagut
Journal: Annals of Oncology (2022)

Cholangiocarcinoma (CCA) is a rare and heterogeneous cancer with dismal prognosis. At the molecular level, CCA is highly heterogeneous, with multiple druggable alterations some of them with already targeted therapies approved. Accordingly, ESMO has recently recommended NGS tissue testing in routine clinical practice for patients with advanced CCA. However, access to tumor biopsy for CCA is technically difficult in a subset of patients. Sequencing of circulating tumor (ct) DNA (liquid biopsy) is a potential alternative to tissue molecular testing, that overcomes intratumoral heterogeneity with a minimal invasive approach and easy access. We aimed at assessing the feasibility and clinical utility of ctDNA genotyping for patients with advanced CCA in a group of referral Oncology centers across Spain. We genotyped ctDNA from blood samples from patients with advanced CCA, treated between 2019 and 2021 at 9 Spanish University Hospitals. ctDNA sequencing was performed by an NGS-based comprehensive approach using Guardant360™ (G360). ctDNA sequencing data were available for 112 patients. The main clinical characteristics were as follow: median age was 62.5 years (range: 28-86), 62 patients (55.3%) were men, 65 patients (58%) had intrahepatic cholangiocarcinoma, 70 patients (62.5%) had stage IV disease at diagnosis and 98 patients (87.5%) had received cisplatin plus gemcitabine as first-line treatment for advanced disease. Determination of ctDNA was performed at baseline in 36.6% of patients and at the time of progression to first-line treatment in 48 patients (42.8%). 96% of patients had ≥ 1genomic alteration detected. Median number of alterations per patient was 2 and median VAF was 0.5%. 245 genomic alterations (GAs) have been identified among 35 different genes. 89% of GAs identified were SNVs, being the most frequent TP53 (33.9%), KRAS (9.8%), IDH1 (6.5%), ATM (6.5%), PIK3CA (4.9%) and ARID1A (4.5%). CNVs accounted for 7.7% of GA and consisted in amplifications of: EGFR (1.6%), MYC (1.6%), BRAF (1.2%) and ERBB2 (0.8%). FGFR2 and FGFR3 fusions were identified in 1.2% and 0.4% patients, respectively. High-microsatellite instability was identified in 1.2% of patients. These findings are similar to previously reported data on tissue molecular profiling in CCA. Importantly, sixty-seven patients (53%) had GA considered as actionable, including three patients with FGFR2 fusions, for which Pemigatinib is approved. ctDNA genotyping for molecular profiling of advanced cholangiocarcinoma patients is feasible and a non-invasive procedure, especially relevant for CCA patients in which increase in actionable biomarkers and insufficient tissue availability is becoming a challenge.
P-76 Phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD)
Authors: N. Sugimoto, K. Nakata, M. Miyo, S. Yoshioka, Y. Kagawa, A. Naito, M. Tei, H. Tamagawa, K. Konishi, H. Osawa, T. Shingai, K. Danno, N. Nishida, G. Sato, T. Shimokawa, N. Miyoshi, H. Takahashi, M. Uemura, H. Yamamoto, K. Murata, Y. Doki, H. Eguchi
Journal: Annals of Oncology (2022)
“Spider-traction” endoscopic submucosal dissection for a submucosal lesion invading the site of a previous appendectomy
Authors: Borathchakra Oung, Jérémie Albouys, Sophie Geyl, Romain Legros, Thomas Lambin, Mathieu Pioche, Jérémie Jacques
Journal: Endoscopy (2022)

Double clip and rubber band traction-assisted endoscopic submucosal dissection (ESD) has been previously shown to be effective and safe for difficult colonic ESDs, such as those for recurrent lesions with severe fibrosis or for lesions invading the appendiceal orifice [1] [2]. Subepithelial lesions can also be removed by double clip and rubber band traction-assisted ESD [3]. "Spider-traction" ESD was recently reported to improve both the effectiveness and speed of ESD [4].
P-90 First-line anti-EGFR agents (panitumumab or cetuximab) plus chemotherapy in patients with metastatic colorectal cancer: Onco-colon Turkey study subgroup analysis
Authors: A. Isıkdogan, H. Turk, C. Bilir, M. Şendur, B. Karabulut, M. Artac, I. Cicin, C. Geredeli, A. Alacacioglu, U. Kefeli, H. Harputluoglu, O. Bozkurt, E. Cubukcu, D. Tural, A. Sakin, T. Cil, F. Dane, D. Çevik, Ç. Arslan, N. Karadurmus, M. Gumus, S. Yalcin
Journal: Annals of Oncology (2022)
SO-4 Individual participant data network meta-analysis (IPD-NMA) of neoadjuvant chemotherapy or chemoradiotherapy in esophageal or gastro-esophageal junction carcinoma
Authors: M. Faron, M. Cheugoua-Zanetsie, P. Thirion, J. Tierney, D. Cunningham, K. Winter, J. Fu, M. Mauer, J. Shapiro, B. Burmeister, T. Walsh, G. Piessen, F. Klevebro, M. Ychou, A. Van Der Gaast, S. Law, M. Stahl, J. van Sandick, J. Pignon, M. Ducreux, S. Michiels
Journal: Annals of Oncology (2022)
P-270 Updated results of Maria Sklodowska-Curie National Research Institute of Oncology gastric cancer cohort: Indirect comparison between adjuvant chemoradiation and perioperative chemotherapy in gastric cancer patients
Authors: M. Mydlowska, S. Rybski, Z. Guzel-Szczepiorkowska, K. Marcisz-Grzanka, K. Kokoszynska-Brejnakowska, L. Wyrwicz
Journal: Annals of Oncology (2022)